- Home
- BB vs PRAX Comparison
BB vs PRAX Comparison
Compare BB & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BB
- PRAX
- Stock Information
- Founded
- BB 1984
- PRAX 2015
- Country
- BB Canada
- PRAX United States
- Employees
- BB N/A
- PRAX N/A
- Industry
- BB
- PRAX Biotechnology: Pharmaceutical Preparations
- Sector
- BB
- PRAX Health Care
- Exchange
- BB Nasdaq
- PRAX Nasdaq
- Market Cap
- BB 1.5B
- PRAX 1.5B
- IPO Year
- BB 1997
- PRAX 2020
- Fundamental
- Price
- BB $3.64
- PRAX $76.79
- Analyst Decision
- BB Buy
- PRAX Strong Buy
- Analyst Count
- BB 6
- PRAX 9
- Target Price
- BB $3.70
- PRAX $146.33
- AVG Volume (30 Days)
- BB 17.1M
- PRAX 393.5K
- Earning Date
- BB 12-19-2024
- PRAX 11-06-2024
- Dividend Yield
- BB N/A
- PRAX N/A
- EPS Growth
- BB N/A
- PRAX N/A
- EPS
- BB N/A
- PRAX N/A
- Revenue
- BB $638,000,000.00
- PRAX $1,605,000.00
- Revenue This Year
- BB N/A
- PRAX N/A
- Revenue Next Year
- BB $7.65
- PRAX N/A
- P/E Ratio
- BB N/A
- PRAX N/A
- Revenue Growth
- BB N/A
- PRAX N/A
- 52 Week Low
- BB $2.01
- PRAX $19.61
- 52 Week High
- BB $3.85
- PRAX $86.93
- Technical
- Relative Strength Index (RSI)
- BB 73.10
- PRAX 51.17
- Support Level
- BB $2.96
- PRAX $68.42
- Resistance Level
- BB $2.95
- PRAX $73.49
- Average True Range (ATR)
- BB 0.20
- PRAX 4.62
- MACD
- BB 0.06
- PRAX -0.06
- Stochastic Oscillator
- BB 98.40
- PRAX 63.02
About BB BlackBerry Limited
BlackBerry, once known for being the world's largest smartphone manufacturer, is now exclusively a software provider with a stated goal of end-to-end secure communication for enterprises. The firm provides endpoint management and protection to enterprises, specializing in regulated industries like government, as well as embedded software to the automotive, medical, and industrial markets.
About PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The firm's pipeline covers PRAX-114, for the treatment of a broad range of patients suffering from major depressive disorder and post-traumatic stress disorder; PRAX-944, for the treatment of Essential Tremor and Parkinson's Disease; PRAX-562, and PRAX-222, among others.